Patient Profile:
Gregory, 71


  • Diagnosed with high-risk myelodysplastic syndromes (MDS) when a blood examination revealed pancytopenia
  • Bone marrow biopsy indicated 10% blasts and multilineage dysplasia

Blood Test Results

  • Hemoglobin: 6.0 g/dL
  • Red blood cells: 4.1 M/µL
  • White blood cells: 3.0 K/µL
  • ANC: 570 cells/µL*
  • IPSS-R Score of 5.5 points=high
  • Platelets: 76 x 109/L
  • Neutrophils: 16%
  • Cytogenetic category: Good

About Gregory

  • He enjoys fishing and doing outdoor activities with his wife and 2 grandchildren
  • He is transfusion-dependent
  • His treatment team discussed hypomethylating agents due to his IPSS-R Score, but Gregory does not have to have a port placement
  • He would prefer a treatment option that he can take in the convenience of his home
  • ECOG performance status was 1 prior to taking INQOVI

*Bands: 3%

ANC=absolute neutrophil count; ECOG=Eastern Cooperative Oncology Group; IPSS-R=Revised International Prognostic Scoring System; MDS=myelodysplastic syndromes.


Patient Profile:
Diane, 74


  • Diagnosed 6 months ago with intermediate-risk MDS
  • Tests revealed moderate anemia, neutropenia; there was a prior diagnosis of renal disease
  • 11.2% blasts
  • Initiated MDS treatment with IV HMA therapy
  • Began transfusion for anemia, and monitored progress
  • Has since achieved transfusion independence and is stable

Blood Test Results

  • Hemoglobin: 6.5 g/dL
  • Red blood cells: 3.6 M/µL
  • White blood cells: 4.0 K/µL
  • ANC: 800 cells/µL
  • IPSS-R Score of 4.5 points=intermediate
  • Platelets: 103 x 109/L
  • Neutrophils: 18%
  • Cytogenetic category: Very good

About Diane

  • She does not have a full-time caregiver or family member to help with travel; she has been unable to get to the infusion center to complete her most recent cycle
  • She needed a treatment option she could take at home
  • ECOG performance status of 2 prior to beginning INQOVI

Bands: 2%

HMA=hypomethylating agent; IV=intravenous.

Additional Information

Your patients that may be appropriate for INQOVI1:

  • Diagnosed with de novo or secondary MDS, including CMML
  • Classified as intermediate- or high-risk MDS
  • Have been previously treated or are treatment naive

Additional Patient Considerations:

  • Wish to take their HMA therapy in the comfort of their own home
  • Unable to have, or do not wish to have, infusion port placement
  • Do not have regular support to manage travel to the infusion center

Reference: 1. INQOVI [package insert]. Princeton, NJ: Taiho Oncology, Inc.; 2022

Previous Page 

What is INQOVI?

Next Page 

Efficacy & Safety